—LVS
— • —
$53.45
P/E
22.74
PEG
0.01
FCF Yield
—
Rev Growth YoY
+1522.0% YoY
Gross Margin
4765.0%
Health Score
4/10
D/E Ratio
9.93
Confidence
LOW
Business Snapshot
The ticker and exchange identifiers are absent from this data payload, which limits company-specific context. Based on available financial ratios, this appears to be a highly leveraged, fast-growing company with an unusually high return on equity and gross margin figures. Without a confirmed market cap, the cap tier cannot be determined; however, the combination of explosive growth metrics and data gaps is consistent with a smaller, potentially recently restructured or acquisition-driven entity.
Financial Health
Score: 4/10
The balance sheet presents a deeply conflicted picture. Debt/equity stands at a very high 9.93x, indicating the company is substantially funded by debt rather than equity — a fragile position in any rising-rate environment...
Risk Assessment
- DEBT: Debt/equity of 9.93x is extremely high and leaves the company highly vulnerable to rising interest costs or any revenue shortfall.
- DATA QUALITY: TTM Revenue, TTM Net Income, and Free Cash Flow are all unavailable, making comprehensive fundamental analysis impossible and preventing reliable valuation anchoring.
- TECHNICAL WEAKNESS: A confirmed "death cross" (50-day MA crossing below the 200-day MA) is a bearish technical signal, and the MACD is also in bearish territory — both moving averages are above the current price.
- GROWTH SUSTAINABILITY: Revenue growth of 1,522% YoY and a gross margin of 4,765% are statistically implausible figures for a mature operating business and likely reflect base effects, restatements, or data anomalies that require direct verification from filings.
- VALUATION UNCERTAINTY: With no DCF estimate, no TTM revenue, and no FCF yield, there is no reliable way to determine whether the current price of $53.45 represents fair value.
---...
**Score: 4/10** The balance sheet presents a deeply conflicted picture. Debt/equity stands at a very high 9.93x, indicating the company is substantially funded by debt rather than equity — a fragile position in any rising-rate environment. On the positive side, the current ratio of 1.14x suggests the company can just cover short-term liabilities with short-term assets, though there is minimal cushion. Free cash flow is unavailable, which makes it impossible to assess whether earnings are being converted into real cash — a critical gap that prevents a higher health score. ---
- **DEBT:** Debt/equity of 9.93x is extremely high and leaves the company highly vulnerable to rising interest costs or any revenue shortfall. - **DATA QUALITY:** TTM Revenue, TTM Net Income, and Free Cash Flow are all unavailable, making comprehensive fundamental analysis impossible and preventing reliable valuation anchoring. - **TECHNICAL WEAKNESS:** A confirmed "death cross" (50-day MA crossing below the 200-day MA) is a bearish technical signal, and the MACD is also in bearish territory — both moving averages are above the current price. - **GROWTH SUSTAINABILITY:** Revenue growth of 1,522% YoY and a gross margin of 4,765% are statistically implausible figures for a mature operating business and likely reflect base effects, restatements, or data anomalies that require direct verification from filings. - **VALUATION UNCERTAINTY:** With no DCF estimate, no TTM revenue, and no FCF yield, there is no reliable way to determine whether the current price of $53.45 represents fair value. ---
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives